Serum SALL4 Is a Novel Prognosis Biomarker with Tumor Recurrence and Poor Survival of Patients in Hepatocellular Carcinoma

Figure 2

(a) The serum SALL4 levels in HCC and three controls. The concentration of serum SALL4 in HCC was much higher than that in controls (𝑃<0.001). The three control groups had no significant differences. (b) The comparison of serum SALL4 levels (𝑛=52) before and after treatment. The level of serum SALL4 after treatment was higher than before treatment (𝑃<0.002).

(a)

(b)